regadenoson has been researched along with Airflow Obstruction, Chronic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia, CS; Heffernan, AJ; Jimenez Heffernan, A; Lopez Martin, J; Ramos Font, C; Rivera de los Santos, F; Salgado Garcia, C; Sanchez de Mora, E; Ynfante Milá, I | 1 |
| Doukky, R; Golzar, Y | 1 |
| Ananthasubramaniam, K; Cabrera, R; Dhanalakota, S; Husain, Z; Jacobsen, G; Karthikeyan, AS; Palani, G; Pathmanathan, S | 1 |
| Behm, S; Bukofzer, S; Feaheny, K; McNutt, BE; Prenner, BM | 1 |
| Thompson, RC | 1 |
1 review(s) available for regadenoson and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.
Topics: Adenosine A2 Receptor Agonists; Asthma; Coronary Artery Disease; Echocardiography, Stress; Exercise Test; Humans; Lung; Myocardial Perfusion Imaging; Patient Selection; Predictive Value of Tests; Prognosis; Pulmonary Disease, Chronic Obstructive; Purines; Pyrazoles; Risk Factors; Severity of Illness Index; Vasodilator Agents | 2014 |
1 trial(s) available for regadenoson and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
Topics: Adenosine A2 Receptor Antagonists; Adult; Aged; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Incidence; Male; Middle Aged; Myocardial Perfusion Imaging; Placebos; Pulmonary Disease, Chronic Obstructive; Purinergic P1 Receptor Agonists; Purines; Pyrazoles; Reproducibility of Results | 2012 |
3 other study(ies) available for regadenoson and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.
Topics: Adult; Aged; Aged, 80 and over; Asthma; Blood Pressure; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Purines; Pyrazoles; Safety; Stress, Physiological | 2014 |
Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.
Topics: Adenosine A2 Receptor Antagonists; Aged; Asthma; Atrioventricular Block; Bronchoconstriction; Chi-Square Distribution; Female; Heart Diseases; Hemodynamics; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Organophosphorus Compounds; Organotechnetium Compounds; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Purines; Pyrazoles; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Risk Factors; Tachycardia, Supraventricular; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2012 |
Regadenoson stress in patients with asthma and COPD: a breath of fresh air.
Topics: Adenosine A2 Receptor Antagonists; Asthma; Female; Humans; Male; Myocardial Perfusion Imaging; Pulmonary Disease, Chronic Obstructive; Purines; Pyrazoles | 2012 |